公开(公告)号：US20240325313A1

公开(公告)日：2024-10-03

申请号：US18592784

申请日：2024-03-01

申请人： RedHill Biopharma Ltd.

发明人： Reza Fathi ,  Gilead Raday ,  Guy Goldberg ,  Patrick Gosselin

IPC分类号： A61K9/48 ,  A61K9/50 ,  A61K31/395 ,  A61K31/43 ,  A61K31/435 ,  A61K31/438 ,  A61K31/4439

CPC分类号： A61K9/4808 ,  A61K9/4866 ,  A61K9/4891 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/395 ,  A61K31/43 ,  A61K31/435 ,  A61K31/438 ,  A61K31/4439

摘要： Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.

公开(公告)号：US20240317743A1

公开(公告)日：2024-09-26

申请号：US18589022

申请日：2024-02-27

申请人： BeiGene, Ltd. ,  BeiGene Switzerland GmbH

发明人： Desheng Yu ,  Gongyin Shi ,  Hai Xue ,  Yunhang Guo

IPC分类号： C07D471/04 ,  A61K31/438

CPC分类号： C07D471/04 ,  A61K31/438

摘要： The present invention relates to a solid form, particularly a crystalline forms of Bcl-2 inhibitor 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((S)-2-(2-isopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide, pharmaceutical compositions comprising the solid form, processes for preparing the solid form, and methods of use therefore.

公开(公告)号：US12077540B2

公开(公告)日：2024-09-03

申请号：US17856915

申请日：2022-07-01

申请人： The Board of Regents of The University of Texas System

发明人： Jia Zhou ,  Pei-Yong Shi ,  Jimin Xu ,  Xuping Xie

IPC分类号： A61K31/438 ,  A61P31/14 ,  C07D471/20 ,  C07D495/04

CPC分类号： C07D471/20 ,  A61K31/438 ,  A61P31/14 ,  C07D495/04

摘要： A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3′-indoline]-2′,5(3H)-dione analogues, the use thereof and the preparation thereof.

公开(公告)号：US12077536B2

公开(公告)日：2024-09-03

申请号：US17750821

申请日：2022-05-23

申请人： BEIGENE, LTD.

发明人： Yunhang Guo ,  Hai Xue ,  Zhiwei Wang ,  Hanzi Sun

IPC分类号： A61K31/496 ,  A61K31/438 ,  A61P35/00 ,  C07D403/12 ,  C07D405/14 ,  C07D471/04 ,  C07D471/14 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61P35/00 ,  C07D403/12 ,  C07D405/14 ,  C07D471/14 ,  C07D519/00

摘要： Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

公开(公告)号：US12076405B2

公开(公告)日：2024-09-03

申请号：US17164446

申请日：2021-02-01

申请人： C4 Therapeutics, Inc.

发明人： Andrew J. Phillips ,  Christopher G. Nasveschuk ,  James A. Henderson ,  Yanke Liang ,  Mark E. Fitzgerald ,  Minsheng He ,  Ryan E. Michael

IPC分类号： A61K47/54 ,  A61K31/4035 ,  A61K31/438 ,  A61K31/439 ,  A61K31/454 ,  A61K31/547 ,  A61K31/55 ,  C07D401/04 ,  C07D403/04

CPC分类号： A61K47/545 ,  A61K31/4035 ,  A61K31/438 ,  A61K31/439 ,  A61K31/454 ,  A61K31/547 ,  A61K31/55 ,  A61K47/554 ,  C07D403/04

摘要： This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

公开(公告)号：US20240269149A1

公开(公告)日：2024-08-15

申请号：US18454012

申请日：2023-08-22

申请人： UNIVERSITY OF IOWA RESEARCH FOUNDATION ,  THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

发明人： Christopher M. ADAMS ,  Steven D. KUNKEL ,  Michael WELSH

IPC分类号： A61K31/58 ,  A61K31/215 ,  A61K31/352 ,  A61K31/353 ,  A61K31/36 ,  A61K31/382 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/436 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4706 ,  A61K31/473 ,  A61K31/56 ,  A61K31/565 ,  C12Q1/6809 ,  G01N33/50

CPC分类号： A61K31/58 ,  A61K31/215 ,  A61K31/352 ,  A61K31/353 ,  A61K31/36 ,  A61K31/382 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/436 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4706 ,  A61K31/473 ,  A61K31/56 ,  A61K31/565 ,  C12Q1/6809 ,  G01N33/5023 ,  C12Q2600/136 ,  G01N2800/10 ,  G01N2800/52

摘要： The invention provides a method for (a) increasing skeletal muscle mass; (b) reducing skeletal muscle atrophy; (c) increasing muscular strength; (d) promoting muscle growth; (e) decreasing muscle wasting; or (f) increasing strength per unit of muscle mass in an animal identified or having been identified to be in need of one or more of (a)-(f), the method comprising administering to the animal an effective amount of a compound of formula:




or a stereoisomer, solvate, or pharmaceutically acceptable salt thereof, thereby accomplishing one or more of (a)-(f).

公开(公告)号：US20240261288A1

公开(公告)日：2024-08-08

申请号：US18273411

申请日：2022-01-25

申请人： lkena Oncology, Inc.

发明人： Alfredo C. CASTRO ,  Michael BURKE ,  Benjamin AMIDON ,  Hyejin FROSCH

IPC分类号： A61K31/519 ,  A61K31/085 ,  A61K31/136 ,  A61K31/167 ,  A61K31/18 ,  A61K31/403 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/427 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/4725 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K31/519 ,  A61K31/085 ,  A61K31/136 ,  A61K31/167 ,  A61K31/18 ,  A61K31/403 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/427 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/4725 ,  A61P35/00 ,  C07K16/2863 ,  A61K2039/505

摘要： The present invention provides TEAD inhibitors, and methods of use thereof.

公开(公告)号：US20240245663A1

公开(公告)日：2024-07-25

申请号：US18623761

申请日：2024-04-01

申请人： Lumos Pharma, Inc.

发明人： Alpa B. Parikh ,  John C. McKew

IPC分类号： A61K31/438 ,  A61K9/20 ,  A61K9/28 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P5/06

CPC分类号： A61K31/438 ,  A61K9/2077 ,  A61K9/2846 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P5/06

摘要： The present disclosure relates to pharmaceutical solid forms and pharmaceutical compositions comprising ibutamoren or a pharmaceutically acceptable salt thereof, and methods for administering to a pediatric subject for treating growth hormone deficiency.

公开(公告)号：US20240239781A1

公开(公告)日：2024-07-18

申请号：US18556504

申请日：2022-04-19

申请人： ACONDICIONAMIENTO TARRASENSE

发明人： Ana Virginia LLORENTE-FERNÁNDEZ ,  Carmen ALMANSA-ROSALES ,  Mónica GARCÍA-LÓPEZ ,  Ute CHRISTMANN ,  Jose Luís DÍAZ-FERNÁNDEZ

IPC分类号： C07D413/14 ,  A61K31/407 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/438 ,  A61K31/444 ,  A61K31/553 ,  C07D401/14 ,  C07D403/14 ,  C07D471/10 ,  C07D487/10 ,  C07D498/04

CPC分类号： C07D413/14 ,  A61K31/407 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/438 ,  A61K31/444 ,  A61K31/553 ,  C07D401/14 ,  C07D403/14 ,  C07D471/10 ,  C07D487/10 ,  C07D498/04

摘要： The present invention relates to new 1H-pyrazole derivatives of formula (I) as sigma ligands having a great affinity for sigma receptors, especially the sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2), as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.

公开(公告)号：US20240190875A1

公开(公告)日：2024-06-13

申请号：US18547364

申请日：2022-04-24

申请人： CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD.

发明人： Yunlong SONG ,  Guangyuan SHEN ,  Peng LIU ,  Lei JIN ,  Guocheng WANG ,  Daizong LIN ,  Guosheng TENG ,  Hongbo YAN

IPC分类号： C07D471/10 ,  A61K31/438

CPC分类号： C07D471/10 ,  A61K31/438

摘要： A compound of Formula I, or a racemate, a racemate, a stereoisomer, a tautomer, an isotopically labeled compound, an N-oxide, a solvate, a polymorph, a metabolite, an ester, a prodrug or a pharmaceutically acceptable salt thereof are provided. Also provided is a pharmaceutical composition containing the compound of Formula I and derivatives, a preparation method therefor, and use thereof as a GHSR agonist in the preparation of drugs for diagnosing, preventing and/or treating growth hormone dependent disease. The structure of Formula I is shown below: